Saturday 17 October 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
59.24
1.75
−2.87%
Follow PTCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 20.64% | 101.97% | (104.75%) | (124.24%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
2 | 1 | 7 | 7 | |
| (1.30%) | (6.76%) | 29.66% | 33.51% | ||
ROIC |
15.16% | (6.74%) | 121.13% | 90.05% | |
Return on Tangible Assets |
(2.02%) | (13.50%) | 50.16% | 62.72% | |
Average Days of Receivables |
86.49 | 97.05 | 38.30 | 41.66 | |
Free Cash Flow per Share |
(3.62) | (5.85) | 8.83 | 5.69 | |
Free Cash Flow |
(300.25) | (482.67) | 702.41 | 446.32 | |
Capital Expenditures |
(269.74) | (264.72) | (8.79) | (269.15) | |
| Other line items | |||||
Cash ROIC |
(6.03%) | (11.16%) | 16.19% | 11.40% | |
Accounts Receivable Turnover |
4.64 | 3.84 | 10.18 | 8.83 | |
Accounts Payable Turnover |
0.20 | 0.20 | 0.14 | 0.18 | |
Inventory Turnover |
1.13 | 1.28 | 0.91 | 1.28 | |
Average Days of Payables |
1,973.96 | 1,837.65 | 2,960.12 | 1,963.70 | |
Days of Inventory on Hand |
471.76 | 443.59 | 618.36 | 341.30 | |
Tax Rate |
(0.43) | (0.21) | (0.02) | 0.01 | |
Research and Development Expense of Revenue |
42.95% | 54.06% | 26.31% | 25.12% | |
Selling, General and Administrative Expense of Revenue |
34.47% | 42.60% | 20.06% | 18.83% | |
Share Based Compensation of Revenue |
8.39% | 9.66% | 4.31% | 4.12% | |
Interest Coverage |
0.68 | (0.35) | 5.69 | 5.62 | |
Operating CF/Net income |
0.79 | 1.17 | 1.04 | 0.95 | |
Depreciation/Fixed assets |
0.72 | 0.55 | 0.40 | 3.12 | |
Capex/Depreciation |
(7.25) | (9.05) | (0.40) | (1.51) | |
Revenue per Share |
12.15 | 10.02 | 21.76 | 22.67 | |
Operating CF per Share |
(0.37) | (2.64) | 8.94 | 9.12 | |
Capex per Share |
(3.25) | (3.21) | (0.11) | (3.43) | |
Capex to Sales |
0.27 | 0.32 | 0.01 | 0.15 |
Columns are period end dates